Ascentage Pharma Group International
AAPG37.520USD
+0.320+0.86%
Market hours （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Ascentage Pharma Group International Company
Ascentage Pharma Group International is a holding company primarily engaged in discovering, developing and commercializing therapies primarily in hematological malignancies. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The Company mainly conducts its business in the domestic market.
Company Info
Ticker SymbolAAPG
Company nameAscentage Pharma Group International
IPO dateOct 28, 2019
CEODr. Dajun Yang, M.D., Ph.D.
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
Address68 Xinqing Road, Suzhou Industrial Park
CitySUZHOU
Stock exchangeNASDAQ Global Market Consolidated
CountryChina
Postal code- -
Phone
Websitehttps://www.ascentage.cn/
Ticker SymbolAAPG
IPO dateOct 28, 2019
CEODr. Dajun Yang, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
,
,
Senior Vice President - Global Corporate Development and Finance
Senior Vice President - Global Corporate Development and Finance
--
--
Veet Misra
Veet Misra
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Jin Cao
Mr. Jin Cao
Head - Finance
Head - Finance
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
,
,
Senior Vice President - Global Corporate Development and Finance
Senior Vice President - Global Corporate Development and Finance
--
--
Veet Misra
Veet Misra
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Monashee Investment Management, LLC
0.17%
Point72 (DIFC) Ltd
0.03%
XY Capital Ltd.
0.03%
Voloridge Investment Management, LLC
0.02%
Verition Fund Management LLC
0.01%
Other
99.75%
Shareholders
Shareholders
Proportion
Monashee Investment Management, LLC
0.17%
Point72 (DIFC) Ltd
0.03%
XY Capital Ltd.
0.03%
Voloridge Investment Management, LLC
0.02%
Verition Fund Management LLC
0.01%
Other
99.75%
Shareholder Types
Shareholders
Proportion
Hedge Fund
0.18%
Investment Advisor
0.06%
Investment Advisor/Hedge Fund
0.02%
Other
99.74%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
7
238.19K
0.26%
+238.19K
2025Q1
6
237.19K
0.27%
+237.19K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Monashee Investment Management, LLC
159.94K
0.18%
+159.94K
--
Mar 31, 2025
Point72 (DIFC) Ltd
25.40K
0.03%
+25.40K
--
Mar 31, 2025
XY Capital Ltd.
23.50K
0.03%
+23.50K
--
Mar 31, 2025
Voloridge Investment Management, LLC
15.94K
0.02%
+15.94K
--
Mar 31, 2025
Verition Fund Management LLC
9.92K
0.01%
+9.92K
--
Mar 31, 2025
UBS Financial Services, Inc.
2.48K
0%
+2.48K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco Golden Dragon China ETF
0.03%
Invesco Golden Dragon China ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
